文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Update on advances in molecular PET in urological oncology.

作者信息

Kitajima Kazuhiro, Yamamoto Shingo, Fukushima Kazuhito, Minamimoto Ryogo, Kamai Takao, Jadvar Hossein

机构信息

Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medical Center, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.

Department of Urology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.

出版信息

Jpn J Radiol. 2016 Jul;34(7):470-85. doi: 10.1007/s11604-016-0553-3. Epub 2016 May 24.

DOI:10.1007/s11604-016-0553-3
PMID:27222021
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5412592/
Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of (18)F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. (18)F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.

摘要

相似文献

[1]
Update on advances in molecular PET in urological oncology.

Jpn J Radiol. 2016-7

[2]
FDG in Urologic Malignancies.

PET Clin. 2014-10

[3]
Positron-emission tomography imaging in urological oncology: Current aspects and developments.

Int J Urol. 2018-11

[4]
18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.

Invest Radiol. 2016-3

[5]
Role of positron emission tomography in urological oncology.

BJU Int. 2010-12

[6]
PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.

Eur J Radiol. 2016-4

[7]
Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Invest Radiol. 2016-1

[8]
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for Lung Cancer Staging.

J Thorac Imaging. 2016-7

[9]
Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.

J Pediatr Hematol Oncol. 2019-10

[10]
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.

Int J Urol. 2010-4-1

引用本文的文献

[1]
Disseminated Carcinomatosis of the Bone Marrow from Castration-Resistant Prostate Cancer Revealed by Choline Positron Emission Tomography-Computed Tomography.

Case Rep Oncol. 2024-6-11

[2]
Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer.

Curr Oncol. 2022-7-7

[3]
Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence features.

Sci Rep. 2021-5-20

[4]
Delayed F-FDG PET/CT Appearance of Urachal Adenocarcinomas.

Contrast Media Mol Imaging. 2020

[5]
Delayed post-diuretic F-FDG PET/CT for preoperative evaluation of renal pelvic cancer.

J Cancer. 2020-4-6

[6]
F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma.

Nucl Med Mol Imaging. 2019-8

[7]
F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study.

Cancers (Basel). 2019-5-20

[8]
F-FDG and C-choline uptake in proliferating tumor cells is dependent on the cell cycle in vitro.

Ann Nucl Med. 2019-4

[9]
FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.

Clin Exp Med. 2018-11-28

[10]
Radiobiological Characterization of CuCl₂ as a Simple Tool for Prostate Cancer Theranostics.

Molecules. 2018-11-11

本文引用的文献

[1]
Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.

Transl Oncol. 2016-4

[2]
FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.

Eur J Radiol. 2016-3

[3]
Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Eur J Nucl Med Mol Imaging. 2016-1

[4]
Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

J Nucl Med. 2015-10-22

[5]
Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.

J Nucl Med. 2015-9-24

[6]
Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.

Eur Radiol. 2016-6

[7]
18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.

Eur J Endocrinol. 2015-9-7

[8]
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.

Cancer Imaging. 2015-9-3

[9]
Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.

Eur J Nucl Med Mol Imaging. 2016-3

[10]
Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?

Abdom Imaging. 2015-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索